Interferon-β-1b: In newly emerging multiple sclerosis

CNS Drugs

Volumn 22, Issue 9, 2008, Pages 787-792

  McKeage, Kate ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Immunomodulators, therapeutic use; Interferon beta 1b, adverse reactions; Interferon beta 1b, pharmacodynamics; Interferon beta 1b, pharmacokinetics; Interferon beta 1b, therapeutic use; Multiple sclerosis

Indexed keywords

EXTAVIA; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD BRAIN BARRIER; CONFIDENCE INTERVAL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; HAZARD RATIO; HUMAN; IMMUNOREGULATION; INCIDENCE; INJECTION SITE REACTION; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 49549097110     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822090-00005     Document Type: Review

References (14)

1. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology 2002; 59 Suppl. 3: S1-33
2. The National Collaborating Centre for Chronic Conditions. Multiple sclerosis: national clinical guidance for diagnosis and management in primary and secondary care [online]. Available from URL: http://www.rcplondon.ac.uk/ pubs/books/MS/MSfulldocument.pdf [Accessed 2008 Jun 10]
3. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 2003; 63 (15): 1525-33
4. Stuve O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs 2008; 68 (1): 73-83
5. Electronic Medicines Compendium. Betaferon® 250 μg/mL: summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk/emc/assets/c/html [Accessed 2008 Jun 10]
6. McCormack PL, Scott LJ. Interferon-β-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 2004; 18 (8): 521-46
7. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 Aug 4; 370 (9585): 389-97
8. Betaseron® (interferon beta-1b) for sc injection: US prescribing information. Montville (NJ): Bayer HealthCare Pharmaceuticals Inc, 2007
9. Karabudak R, Kurne A, Guc D, et al. Effect of interferon β-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metaaoproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients: one year follow up results. J Neurol 2004: 251: 279-83
10. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-9
11. ser in healthy volunteers and its effect on serum neopterin. Pharm Res 1993 Apr; 10 (4): 567-72
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13 (3): 227-31
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50 (1): 121-7
14. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82